Malvern Panalytical

Malvern Panalytical and Applied Photophysics announce distribution agreement for Protein Stable’s SUPR-DSF

Partnership targets high-throughput protein stability screening to accelerate drug development

14 November 2022 - Malvern Panalytical (Malvern, UK) and Applied Photophysics (Leatherhead, UK) have today announced their commercial agreement for Malvern Panalytical to distribute Protein Stable’s microplate-based differential scanning fluorimeter, SUPR-DSF, in the United States of America and Canada.

The SUPR-DSF provides researchers with high-throughput protein stability screening using the technique of Differential Scanning Fluorimetry (DSF). Its speed of analysis, 384-well plate format, ultra-low sample volume requirement and low running costs enable the SUPR-DSF to flexibly support scientists working in biologics discovery, formulation development and process development.

Malvern Panalytical offers a broad, integrated range of technologies and contract services to its customers in the pharmaceutical industry, supporting all stages of development from discovery through to commercial manufacturing. The scientific instrument manufacturer, a member of the Spectris Group, recently consolidated its provision for drug discovery and development with its acquisition of Creoptix AG and its WAVEsystem technology for next-generation molecular interaction analysis. The addition of DSF as a high-throughput screening (HTS) tool further extends and strengthens the company’s existing portfolio for stability and structural analysis. This, coupled with Malvern Panalytical’s decades of expertise and experience, provides customers with a unique toolset which empowers them to make important decisions in candidate and formulation selection with absolute confidence.

Dr. Mark Carnegie-Brown, Vice-President, Pharma & Food Sector at Malvern Panalytical, said: “This distribution agreement for Protein Stable’s SUPR-DSF perfectly complements Malvern Panalytical’s existing expertise in pharmaceutical discovery and early development. The addition of DSF to our portfolio of structure, stability and interaction analysis solutions provides a significant uplift to the value we deliver to our clients, magnifying the analytical power at their fingertips and enabling them to bring safe and effective pharmaceutical products to market quickly and efficiently.”

Dr Tim Flanagan, CEO at Applied Photophysics & Protein Stable, said: “we developed the SUPR-DSF to solve critical challenges in protein stability screening - how to simplify sample processing, screen many samples in good time, without using large quantities of expensive protein, and delivering rich data to inform downstream development. Our partnership with Malvern Panalytical extends our market reach, ensuring more researchers can gain access to our combined extensive orthogonal tool set, enabling them to unlock the development of exciting new biologics-based therapies.”

For further details, please visit our website, and learn more about the capabilities of the SUPR-DSF in our launch webinar on December 6th, 2022.

Reader enquiries

Malvern Panalytical B.V.
Lelyweg 1
7602 EA Almelo





Notes for editors

About Malvern Panalytical

We draw on the power of our analytical instruments and services to make the invisible visible and the impossible possible. Through the chemical, physical and structural analysis of materials, our high precision analytical systems and top-notch services support our customers in creating a better world. We help them improve everything from the energies that power us and the materials we build with, to the medicines that cure us and the foods we enjoy.

We partner with many of the world’s biggest companies, universities and research organizations. They value us not only for the power of our solutions, but also for the depth of our expertise, collaboration and integrity. We are committed to Net Zero in our own operations by 2030 and in our total value chain by 2040. This is woven into the fabric of our business, and we help our employees and customers think about their part in creating a healthier, cleaner, and more productive world. With over 2300 employees, we serve the world, and we are part of Spectris plc, the world-leading precision measurement group.

About Applied Photophysics

Applied Photophysics, headquartered in Leatherhead, Surrey, UK, is a leading provider of solutions for biophysical characterization of biomolecules. Chirascan™ systems use the phenomenon of circular dichroism (CD) to characterize changes in the higher order structure of proteins. These systems are used in cutting-edge research and to support the development of innovator drugs and biosimilars in the biopharmaceutical industry. The company’s SX-range of stopped-flow spectrometers is acknowledged globally as the gold standard for kinetic studies of fast biochemical reactions.  Through a joint venture with Fluorescence Innovations Inc of Minneapolis, MN, USA, operating as Protein Stable, we have also introduced easy-to-use high-throughput protein stability screening with microplate-based intrinsic fluorescence thermal ramping and chemical melt plate readers.

Related images


Editorial enquiries

Iris Kisjes
Malvern Panalytical B.V.

+31 628 835 706


Stephanie Wakkee

+31 164 317 038





More news from